ANAPTYSBIO, INC (ANAB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80M 160M 240M Q4 '16: 16.7M Q1 '17: 11.8M Q2 '17: 13M Q3 '17: 9.8M Q4 '17: 10M Q1 '18: 10M Q2 '18: 3M Q3 '18: 8M Q4 '18: 5M Q1 '19: 5M Q2 '19: 10M Q3 '19: 5M Q4 '19: 8M Q1 '20: 23M Q2 '20: 18M Q3 '20: 18M Q4 '20: 75M Q1 '21: 71.2M Q2 '21: 101.3M Q3 '21: 122.2M Q4 '21: 63.2M Q1 '22: 52.9M Q2 '22: 24.1M Q3 '22: 4.5M Q4 '22: 10.3M Q1 '23: 10.7M Q2 '23: 12.9M Q3 '23: 15M Q4 '23: 17.2M Q1 '24: 23M Q2 '24: 30.5M Q3 '24: 57.2M Q4 '24: 91.3M Q1 '25: 111.9M Q2 '25: 123.2M Q3 '25: 169.5M Q4 '25: 234.6M Q1 '26: 232.4M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '16: -3M Q1 '17: -11.9M Q2 '17: -16.8M Q3 '17: -24.8M Q4 '17: -28.8M Q1 '18: -34.5M Q2 '18: -46.4M Q3 '18: -54.2M Q4 '18: -66.7M Q1 '19: -75.7M Q2 '19: -88M Q3 '19: -104.8M Q4 '19: -107.4M Q1 '20: -92.9M Q2 '20: -88.9M Q3 '20: -79.5M Q4 '20: -23.9M Q1 '21: -32M Q2 '21: -9.9M Q3 '21: 7.7M Q4 '21: -56.8M Q1 '22: -70.2M Q2 '22: -97.5M Q3 '22: -120.3M Q4 '22: -115.2M Q1 '23: -127.8M Q2 '23: -140.2M Q3 '23: -148.2M Q4 '23: -164.4M Q1 '24: -162.2M Q2 '24: -162.4M Q3 '24: -147.4M Q4 '24: -114.9M Q1 '25: -100.3M Q2 '25: -86.1M Q3 '25: -28.7M Q4 '25: 47.9M Q1 '26: 40.8M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '16: -4.3M Q1 '17: -14.8M Q2 '17: -19.8M Q3 '17: -27.8M Q4 '17: -30.1M Q1 '18: -33.7M Q2 '18: -44.7M Q3 '18: -51.5M Q4 '18: -61.7M Q1 '19: -68.6M Q2 '19: -79M Q3 '19: -94.1M Q4 '19: -97.3M Q1 '20: -83.5M Q2 '20: -81.1M Q3 '20: -73.8M Q4 '20: -19.9M Q1 '21: -29.8M Q2 '21: -8.7M Q3 '21: 8.4M Q4 '21: -57.8M Q1 '22: -75.9M Q2 '22: -108M Q3 '22: -134.8M Q4 '22: -128.7M Q1 '23: -136.7M Q2 '23: -144M Q3 '23: -147.8M Q4 '23: -163.6M Q1 '24: -163.3M Q2 '24: -170.1M Q3 '24: -165.7M Q4 '24: -145.2M Q1 '25: -140.6M Q2 '25: -132.6M Q3 '25: -84.6M Q4 '25: -13.2M Q1 '26: -26.8M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q4 '16: -9M Q1 '17: -15.1M Q2 '17: -19.4M Q3 '17: -20.2M Q4 '17: -19.4M Q1 '18: -23.8M Q2 '18: -30.1M Q3 '18: -41M Q4 '18: -48.5M Q1 '19: -52.1M Q2 '19: -58.8M Q3 '19: -66M Q4 '19: -69.5M Q1 '20: -68.5M Q2 '20: -72.6M Q3 '20: -67.5M Q4 '20: -14.2M Q1 '21: -22.2M Q2 '21: 7M Q3 '21: 17M Q4 '21: -45.9M Q1 '22: -43.7M Q2 '22: -77.5M Q3 '22: -88.2M Q4 '22: -73.6M Q1 '23: -77.1M Q2 '23: -78.4M Q3 '23: -97.1M Q4 '23: -120.8M Q1 '24: -133.5M Q2 '24: -129.4M Q3 '24: -103M Q4 '24: -135.3M Q1 '25: -108.8M Q2 '25: -127.7M Q3 '25: -145M Q4 '25: 19.7M Q1 '26: 4.5M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q4 '16: -9.1M Q1 '17: -15.2M Q2 '17: -19.5M Q3 '17: -20.4M Q4 '17: -19.7M Q1 '18: -24.3M Q2 '18: -30.7M Q3 '18: -42M Q4 '18: -49.6M Q1 '19: -53.1M Q2 '19: -59.7M Q3 '19: -66.9M Q4 '19: -70.3M Q1 '20: -69.2M Q2 '20: -73.2M Q3 '20: -67.9M Q4 '20: -14.7M Q1 '21: -23M Q2 '21: 5.4M Q3 '21: 15.3M Q4 '21: -47.3M Q1 '22: -44.8M Q2 '22: -77.8M Q3 '22: -88.4M Q4 '22: -74M Q1 '23: -77.6M Q2 '23: -79M Q3 '23: -97.8M Q4 '23: -121.6M Q1 '24: -134.1M Q2 '24: -129.9M Q3 '24: -103.4M Q4 '24: -135.7M Q1 '25: -109.2M Q2 '25: -128.1M Q3 '25: -145.3M Q4 '25: 19.6M Q1 '26: 4.4M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '16: 3.5M Q3 '16: 2.6M Q2 '17: 20.3M Q3 '17: 20.4M Q2 '20: 27.3M Q3 '20: 27.3M Q1 '21: 27.4M Q2 '21: 27.4M Q3 '21: 27.4M Q1 '22: 27.7M Q2 '22: 28.2M Q3 '22: 28.3M Q1 '23: 28M Q2 '23: 26.6M Q3 '23: 26.5M Q1 '24: 26.8M Q2 '24: 27.4M Q3 '24: 28.9M Q1 '25: 30.6M Q2 '25: 28.8M Q3 '25: 29M Q1 '26: 28.7M Q2 '16 Q3 '17 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q2 '17: -3.03 Q3 '17: -3.06 Q4 '17: -1.63 Q1 '18: -1.51 Q2 '18: -1.95 Q3 '18: -2.16 Q4 '18: -2.50 Q1 '19: -2.69 Q2 '19: -3.01 Q3 '19: -3.50 Q4 '19: -3.61 Q1 '20: -3.09 Q2 '20: -2.99 Q3 '20: -2.71 Q4 '20: -0.73 Q1 '21: -1.09 Q2 '21: -0.32 Q3 '21: 0.31 Q4 '21: -2.11 Q1 '22: -2.76 Q2 '22: -3.89 Q3 '22: -4.83 Q4 '22: -4.57 Q1 '23: -4.84 Q2 '23: -5.19 Q3 '23: -5.42 Q4 '23: -6.08 Q1 '24: -6.14 Q2 '24: -6.35 Q3 '24: -6.08 Q4 '24: -5.15 Q1 '25: -4.79 Q2 '25: -4.42 Q3 '25: -2.76 Q4 '25: -0.46 Q1 '26: -1.02 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.